|This article needs additional or better citations for verification. (June 2017) (Learn how and when to remove this template message)|
|Chemical and physical data|
|Molar mass||143.87 kg/mol|
|(what is this?)|
Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis, but data was not released. Development was discontinued in August 2011.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.
- [dead link]
- "Living Medical eTextbook - Rheumatology - Projects In Knowledge - Rheumatoid Arthritis Edition Table of Contents - Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Lmt.projectsinknowledge.com. p. 4. Retrieved 2017-06-07.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|